FR2919804B1 - Composition et vaccin therapeutique anti-tumoral - Google Patents
Composition et vaccin therapeutique anti-tumoralInfo
- Publication number
- FR2919804B1 FR2919804B1 FR0705767A FR0705767A FR2919804B1 FR 2919804 B1 FR2919804 B1 FR 2919804B1 FR 0705767 A FR0705767 A FR 0705767A FR 0705767 A FR0705767 A FR 0705767A FR 2919804 B1 FR2919804 B1 FR 2919804B1
- Authority
- FR
- France
- Prior art keywords
- red blood
- blood cells
- composition
- cells
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 229940021747 therapeutic vaccine Drugs 0.000 title 1
- 210000003743 erythrocyte Anatomy 0.000 abstract 6
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 206010057249 Phagocytosis Diseases 0.000 abstract 1
- 229940022399 cancer vaccine Drugs 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000036755 cellular response Effects 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 210000004443 dendritic cell Anatomy 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 230000008782 phagocytosis Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001122—Ephrin Receptors [Eph]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/001139—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/001149—Cell cycle regulated proteins, e.g. cyclin, CDC, CDK or INK-CCR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
- A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001158—Proteinases
- A61K39/001159—Matrix metalloproteinases [MMP]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001162—Kinases, e.g. Raf or Src
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001188—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001189—PRAME
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001191—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001192—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001196—Fusion proteins originating from gene translocation in cancer cells
- A61K39/001197—Breakpoint cluster region-abelson tyrosine kinase [BCR-ABL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
Priority Applications (22)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0705767A FR2919804B1 (fr) | 2007-08-08 | 2007-08-08 | Composition et vaccin therapeutique anti-tumoral |
US12/672,094 US9364504B2 (en) | 2007-08-08 | 2008-08-08 | Compostition and therapeutic anti-tumour vaccine |
PL08787072T PL2185164T3 (pl) | 2007-08-08 | 2008-08-08 | Kompozycja i terapeutyczna szczepionka przeciwnowotworowa |
EP08787072.1A EP2185164B1 (fr) | 2007-08-08 | 2008-08-08 | Composition et vaccin anti-tumoral thérapeutique |
CA2695478A CA2695478C (fr) | 2007-08-08 | 2008-08-08 | Composition et vaccin anti-tumoral therapeutique |
HUE08787072A HUE035983T2 (hu) | 2007-08-08 | 2008-08-08 | Készítmény és terápiás tumorellenes oltóanyag |
CN200880110270.0A CN101873862B (zh) | 2007-08-08 | 2008-08-08 | 组合物和治疗性抗肿瘤疫苗 |
PT87870721T PT2185164T (pt) | 2007-08-08 | 2008-08-08 | Composição e vacina anti-tumoral terapêutica |
DK08787072.1T DK2185164T3 (da) | 2007-08-08 | 2008-08-08 | Sammensætning og terapeutisk antitumorvaccine |
NO08787072A NO2185164T3 (fr) | 2007-08-08 | 2008-08-08 | |
JP2010519476A JP6077195B2 (ja) | 2007-08-08 | 2008-08-08 | 組成物と治療用抗腫瘍ワクチン |
AU2008285595A AU2008285595B2 (en) | 2007-08-08 | 2008-08-08 | Composition and therapeutic anti-tumour vaccine |
KR1020107004794A KR101666041B1 (ko) | 2007-08-08 | 2008-08-08 | 조성물 및 치료용 항종양 백신 |
ES08787072.1T ES2649761T3 (es) | 2007-08-08 | 2008-08-08 | Composición y vacuna antitumoral terapéutica |
PCT/EP2008/060492 WO2009019317A1 (fr) | 2007-08-08 | 2008-08-08 | Composition et vaccin anti-tumoral thérapeutique |
IL203714A IL203714A (en) | 2007-08-08 | 2010-02-04 | A drug containing red blood cell remedy, anti-tumor vaccine containing it and its uses |
HK11102915.5A HK1148688A1 (en) | 2007-08-08 | 2011-03-23 | Composition and therapeutic anti-tumour vaccine |
US15/154,273 US9950049B2 (en) | 2007-08-08 | 2016-05-13 | Composition and therapeutic anti-tumour vaccine |
JP2016170936A JP6352996B2 (ja) | 2007-08-08 | 2016-09-01 | 組成物と治療用抗腫瘍ワクチン |
HRP20171566TT HRP20171566T1 (hr) | 2007-08-08 | 2017-10-16 | Pripravak i terapeutsko anti-tumorsko cjepivo |
US15/961,226 US10780151B2 (en) | 2007-08-08 | 2018-04-24 | Composition and therapeutic anti-tumour vaccine |
US17/000,007 US20210077602A1 (en) | 2007-08-08 | 2020-08-21 | Composition and therapeutic anti-tumour vaccine |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0705767A FR2919804B1 (fr) | 2007-08-08 | 2007-08-08 | Composition et vaccin therapeutique anti-tumoral |
Publications (2)
Publication Number | Publication Date |
---|---|
FR2919804A1 FR2919804A1 (fr) | 2009-02-13 |
FR2919804B1 true FR2919804B1 (fr) | 2010-08-27 |
Family
ID=38982501
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR0705767A Active FR2919804B1 (fr) | 2007-08-08 | 2007-08-08 | Composition et vaccin therapeutique anti-tumoral |
Country Status (18)
Country | Link |
---|---|
US (4) | US9364504B2 (fr) |
EP (1) | EP2185164B1 (fr) |
JP (2) | JP6077195B2 (fr) |
KR (1) | KR101666041B1 (fr) |
CN (1) | CN101873862B (fr) |
AU (1) | AU2008285595B2 (fr) |
CA (1) | CA2695478C (fr) |
DK (1) | DK2185164T3 (fr) |
ES (1) | ES2649761T3 (fr) |
FR (1) | FR2919804B1 (fr) |
HK (1) | HK1148688A1 (fr) |
HR (1) | HRP20171566T1 (fr) |
HU (1) | HUE035983T2 (fr) |
IL (1) | IL203714A (fr) |
NO (1) | NO2185164T3 (fr) |
PL (1) | PL2185164T3 (fr) |
PT (1) | PT2185164T (fr) |
WO (1) | WO2009019317A1 (fr) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2919804B1 (fr) | 2007-08-08 | 2010-08-27 | Erytech Pharma | Composition et vaccin therapeutique anti-tumoral |
WO2010087335A1 (fr) * | 2009-01-27 | 2010-08-05 | 学校法人産業医科大学 | GÈNE DE RÉCEPTEUR D'ANTIGÈNE DE LYMPHOCYTES T, VECTEUR POUR L'EXPRESSION D'UNE CHAÎNE α ET D'UNE CHAÎNE β DE RÉCEPTEUR, ET LYMPHOCYTE T CYTOTOXIQUE |
CN102449484B (zh) * | 2009-05-29 | 2014-08-13 | 霍夫曼-拉罗奇有限公司 | 分离蛋白-1作为癌症标志物 |
US20120207745A1 (en) * | 2009-10-27 | 2012-08-16 | Yann Godfrin | Composition to Induce Specific Immune Tolerance |
CN107058231A (zh) * | 2010-02-11 | 2017-08-18 | 中国人民解放军第二军医大学 | 携带融合蛋白基因的重组腺病毒及其制备方法和应用 |
US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
US9518087B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
WO2012059112A1 (fr) * | 2010-11-01 | 2012-05-10 | Mahmoud Abdel Wahed Rafea | Développement de produits médicaux fondés sur une fonction nouvellement découverte des érythrocytes |
PT2715352T (pt) * | 2011-05-31 | 2019-06-12 | Biogen Ma Inc | Método de avaliação do risco de lmp |
CN102973950B (zh) * | 2011-09-06 | 2015-05-27 | 四川百利药业有限责任公司 | Prame、wt1双价肿瘤dna疫苗 |
CN103958679A (zh) * | 2011-09-09 | 2014-07-30 | 转基因股份有限公司 | 变异型α-辅肌动蛋白-4的抗体 |
BR112014009346B1 (pt) | 2011-10-17 | 2020-09-15 | Massachusetts Institute Of Technology | Entrega intracelular |
US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
US10124336B2 (en) | 2013-08-16 | 2018-11-13 | Massachusetts Institute Of Technology | Selective delivery of material to cells |
CN104415335A (zh) | 2013-09-02 | 2015-03-18 | 北京中康万达医药科技有限公司 | 体内个体化系统免疫治疗方法和装置 |
JP6702866B2 (ja) | 2013-11-18 | 2020-06-03 | ルビウス セラピューティクス, インコーポレイテッド | 合成膜−レシーバー複合体 |
FR3017299B1 (fr) | 2014-02-12 | 2018-05-18 | Erytech Pharma | Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur |
SG11201606761RA (en) | 2014-02-21 | 2016-09-29 | Ecole Polytecnique Federale De Lausanne Epfl Epfl Tto | Glycotargeting therapeutics |
US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
ES2865825T3 (es) | 2014-04-01 | 2021-10-18 | Rubius Therapeutics Inc | Procedimientos y composiciones para inmunomodulación |
WO2016022363A2 (fr) | 2014-07-30 | 2016-02-11 | President And Fellows Of Harvard College | Protéines cas9 comprenant des intéines dépendant de ligands |
JP2017533702A (ja) | 2014-10-31 | 2017-11-16 | マサチューセッツ インスティテュート オブ テクノロジー | 生体分子の免疫細胞への送達 |
EP3218492A4 (fr) | 2014-11-14 | 2018-10-10 | Massachusetts Institute Of Technology | Acheminement de composés et de compositions dans des cellules activé par des perturbations et un champ |
CN107250373A (zh) | 2015-01-12 | 2017-10-13 | 麻省理工学院 | 通过微流体递送实现的基因编辑 |
CA2988996A1 (fr) | 2015-07-09 | 2017-01-12 | Massachusetts Institute Of Technology | Administration de substances a des cellules anucleees |
WO2017041051A1 (fr) | 2015-09-04 | 2017-03-09 | Sqz Biotechnologies Company | Administration intracellulaire de biomolécules à des cellules comprenant une paroi cellulaire |
AU2016324297A1 (en) * | 2015-09-18 | 2018-04-26 | The General Hospital Corporation Dba Massachusetts General Hospital | Compositions having anti-fugetactic properties for treatment of cancer |
WO2017059477A1 (fr) | 2015-10-07 | 2017-04-13 | Sangui Bio Pty. Ltd | Préparation et profilage sanguins |
WO2017106899A2 (fr) * | 2015-12-22 | 2017-06-29 | Sangui Bio Pty. Ltd | Méthodes thérapeutiques utilisant les érythrocytes |
AU2017207738A1 (en) | 2016-01-11 | 2018-07-12 | Rubius Therapeutics, Inc. | Compositions and methods related to multimodal therapeutic cell systems for cancer indications |
CN105646676A (zh) * | 2016-03-17 | 2016-06-08 | 南通大学 | 小分子多肽Prdx5截短体及其载体和应用 |
AU2017308889B2 (en) | 2016-08-09 | 2023-11-09 | President And Fellows Of Harvard College | Programmable Cas9-recombinase fusion proteins and uses thereof |
JP6314201B1 (ja) * | 2016-11-21 | 2018-04-18 | テラファーマ株式会社 | 樹状細胞洗浄液及びこれを用いた樹状細胞の洗浄方法、並びに樹状細胞含有組成物の調製方法 |
AU2017379367B2 (en) | 2016-12-20 | 2023-12-07 | Sangui Bio Pty. Ltd | Blood profiling with protease inhibitors |
US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
WO2018165631A1 (fr) * | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Vaccin contre le cancer |
US11253579B2 (en) | 2017-06-16 | 2022-02-22 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
WO2019023680A1 (fr) | 2017-07-28 | 2019-01-31 | President And Fellows Of Harvard College | Procédés et compositions pour l'évolution d'éditeurs de bases à l'aide d'une évolution continue assistée par phage (pace) |
US20200368285A1 (en) | 2017-08-07 | 2020-11-26 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
US10960071B2 (en) | 2017-08-07 | 2021-03-30 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
WO2019139645A2 (fr) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | Éditeurs de bases à haut rendement comprenant une gam |
US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
CN110078811B (zh) * | 2018-01-25 | 2022-02-11 | 中国医学科学院医药生物技术研究所 | 一种具有抗肿瘤活性的多肽imb-p1及其应用 |
JP6385607B2 (ja) * | 2018-02-13 | 2018-09-05 | テラファーマ株式会社 | 樹状細胞ワクチン |
US11141433B2 (en) * | 2018-03-08 | 2021-10-12 | Rubius Therapeutics, Inc. | Therapeutic cell systems and methods for treating cancer and infectious diseases |
EP3931309A4 (fr) | 2019-02-28 | 2022-12-21 | SQZ Biotechnologies Company | Administration de biomolécules à des pbmc pour modifier une réponse immunitaire |
CA3130488A1 (fr) | 2019-03-19 | 2020-09-24 | David R. Liu | Procedes et compositions pour l'edition de sequences nucleotidiques |
JP2022527003A (ja) | 2019-04-08 | 2022-05-27 | スクイーズ バイオテクノロジーズ カンパニー | 細胞の中へのペイロードの送達のためのシステムにおける使用のためのカートリッジ |
TWI776276B (zh) * | 2019-11-13 | 2022-09-01 | 中國醫藥大學 | 異種組織細胞組合物治療癌症之用途 |
WO2021132636A1 (fr) * | 2019-12-27 | 2021-07-01 | 特定非営利活動法人North East Japan Study Group | Procédé de traitement du cancer et médicament |
GB2614813A (en) | 2020-05-08 | 2023-07-19 | Harvard College | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
WO2021228832A1 (fr) | 2020-05-11 | 2021-11-18 | Erytech Pharma | Vésicules extracellulaires de globules rouges (vecgr) contenant des cargos et procédés d'utilisation et de production de celles-ci |
CN113350499B (zh) * | 2021-06-29 | 2022-06-14 | 贵州医科大学 | 鸡卵清蛋白OVA mRNA在制备非特异性免疫刺激剂中的应用 |
CN114432261B (zh) * | 2022-02-24 | 2023-11-28 | 初源汇企业管理(深圳)合伙企业(有限合伙) | 一种靶向递送疫苗的制备方法及红细胞疫苗 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1051382A (fr) | 1900-01-01 | |||
DE2740053A1 (de) | 1977-09-06 | 1979-05-03 | Klaus Prof Dr Med Gersonde | Verwendung von allosterischen effektoren mit hilfe von lipidvesikeln ueber eine irreversible inkorporierung zwecks verbesserter o tief 2 -entladung des haemoglobins in erythrozyten |
US4327710A (en) | 1980-06-18 | 1982-05-04 | The United States Of America As Represented By The Secretary Of Agriculture | Process for encapsulating additives in resealed erythrocytes for disseminating chemicals via the circulatory system |
FR2529463B1 (fr) | 1982-07-05 | 1986-01-10 | Centre Nat Rech Scient | Procede et dispositif pour l'encapsulation dans les erythrocytes d'au moins une substance a activite biologique, notamment des effecteurs allosteriques de l'hemoglobine et erythrocytes ainsi obtenus |
US4478824A (en) | 1983-08-08 | 1984-10-23 | Franco Robert S | Method for altering red blood cell function and survival |
JPH0235081A (ja) | 1988-07-26 | 1990-02-05 | Agency Of Ind Science & Technol | アルギニン・デイミナーゼおよびその用途 |
JPH0253490A (ja) | 1988-08-16 | 1990-02-22 | Agency Of Ind Science & Technol | アルギニン・デイミナーゼ遺伝子 |
DE58908768D1 (de) | 1988-09-30 | 1995-01-26 | Siemens Ag | Verfahren zum synchronisierten Umtasten eines Polarisationszustandes eines optischen Sendesignals eines optischen Übertragungssystems mit Überlagerungsempfang und Vorrichtung zur Durchführung des Verfahrens. |
JP2900279B2 (ja) | 1989-08-02 | 1999-06-02 | 株式会社ジャパンエナジー | 新規なアルギニンデイミナーゼ、その製造法及び該酵素を有効成分とする制癌剤 |
FR2678512B1 (fr) | 1991-07-03 | 1995-06-30 | Novacell | Machine a internaliser. |
JP3004788B2 (ja) | 1991-10-28 | 2000-01-31 | 株式会社ジャパンエナジー | アルギニンデイミナーゼ発現ベクター、形質転換微生物およびアルギニンデイミナーゼの製造法 |
US5372942A (en) | 1992-02-10 | 1994-12-13 | Coriell Institute For Medical Research | Protease K resistant arginine deiminase, its method of preparation and its use as an anti-neoplastic agent |
EP1466968A3 (fr) | 1993-03-23 | 2006-10-04 | Cbr Laboratories, Inc. | Méthode et appareil pour encapsulation des substances biologiquement actives |
US6218166B1 (en) * | 1994-12-09 | 2001-04-17 | John Wayne Cancer Institute | Adjuvant incorporation into antigen carrying cells: compositions and methods |
US5804183A (en) | 1997-01-31 | 1998-09-08 | Enzon, Inc. | Arginine deminase derived from mycoplasma arthritidis and polymer conjugates containing the same |
AU6542898A (en) * | 1997-03-05 | 1998-09-22 | John Wayne Cancer Institute | Sialyl lewis antigens as targets for immunotherapy |
EP0882448B1 (fr) * | 1997-05-05 | 2005-01-12 | DIDECO S.r.l. | Méthode d'encapsulation d'agents biologiquement actifs dans des erythrocytes et appareil |
US6183738B1 (en) | 1997-05-12 | 2001-02-06 | Phoenix Pharamacologics, Inc. | Modified arginine deiminase |
DE60026313D1 (de) * | 1999-07-23 | 2006-04-27 | Uutech Ltd | Sensibilisierung von roten blutkörperchen gegenüber ultraschall durch einwirkung eines elektrischen feldes |
AU2001275810A1 (en) | 2000-07-27 | 2002-02-13 | Angiolab, Inc. | The pharmaceutical composition comprising arginine deiminase for inhibiting angiogenesis |
WO2002010177A1 (fr) | 2000-08-01 | 2002-02-07 | Gmp Companies, Inc. | Sels ammonium d'inositol hexaphosphate et leurs utilisations |
US7037500B1 (en) * | 2000-09-08 | 2006-05-02 | The Trustees Of Columbia University In The City Of New York | Method for using phagocytic particles and ATP receptors to deliver antigens to MHC class I receptors to induce immunity against microbial pathogens or tumors or to suppress immunity |
DE10335833A1 (de) * | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie |
FR2873925B1 (fr) | 2004-08-05 | 2006-10-13 | Erytech Pharma Soc Par Actions | Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes |
FR2884717B1 (fr) | 2005-04-25 | 2009-07-03 | Erytech Pharma Soc Par Actions | Erythrocytes renfermant de l'arginine deiminase |
FR2919804B1 (fr) | 2007-08-08 | 2010-08-27 | Erytech Pharma | Composition et vaccin therapeutique anti-tumoral |
US20120207745A1 (en) | 2009-10-27 | 2012-08-16 | Yann Godfrin | Composition to Induce Specific Immune Tolerance |
US8530011B2 (en) | 2010-12-13 | 2013-09-10 | Southwall Technologies Inc. | Insulating glass unit with crack-resistant low-emissivity suspended film |
-
2007
- 2007-08-08 FR FR0705767A patent/FR2919804B1/fr active Active
-
2008
- 2008-08-08 AU AU2008285595A patent/AU2008285595B2/en active Active
- 2008-08-08 CN CN200880110270.0A patent/CN101873862B/zh active Active
- 2008-08-08 WO PCT/EP2008/060492 patent/WO2009019317A1/fr active Application Filing
- 2008-08-08 US US12/672,094 patent/US9364504B2/en active Active
- 2008-08-08 NO NO08787072A patent/NO2185164T3/no unknown
- 2008-08-08 JP JP2010519476A patent/JP6077195B2/ja active Active
- 2008-08-08 DK DK08787072.1T patent/DK2185164T3/da active
- 2008-08-08 HU HUE08787072A patent/HUE035983T2/hu unknown
- 2008-08-08 CA CA2695478A patent/CA2695478C/fr active Active
- 2008-08-08 PL PL08787072T patent/PL2185164T3/pl unknown
- 2008-08-08 PT PT87870721T patent/PT2185164T/pt unknown
- 2008-08-08 ES ES08787072.1T patent/ES2649761T3/es active Active
- 2008-08-08 EP EP08787072.1A patent/EP2185164B1/fr active Active
- 2008-08-08 KR KR1020107004794A patent/KR101666041B1/ko active IP Right Grant
-
2010
- 2010-02-04 IL IL203714A patent/IL203714A/en active IP Right Grant
-
2011
- 2011-03-23 HK HK11102915.5A patent/HK1148688A1/xx unknown
-
2016
- 2016-05-13 US US15/154,273 patent/US9950049B2/en active Active
- 2016-09-01 JP JP2016170936A patent/JP6352996B2/ja active Active
-
2017
- 2017-10-16 HR HRP20171566TT patent/HRP20171566T1/hr unknown
-
2018
- 2018-04-24 US US15/961,226 patent/US10780151B2/en active Active
-
2020
- 2020-08-21 US US17/000,007 patent/US20210077602A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2695478C (fr) | 2018-05-08 |
US20210077602A1 (en) | 2021-03-18 |
US20160324946A1 (en) | 2016-11-10 |
NO2185164T3 (fr) | 2018-01-27 |
PL2185164T3 (pl) | 2018-01-31 |
DK2185164T3 (da) | 2017-11-13 |
KR20100075832A (ko) | 2010-07-05 |
US9950049B2 (en) | 2018-04-24 |
PT2185164T (pt) | 2017-11-28 |
US20120009140A1 (en) | 2012-01-12 |
EP2185164A1 (fr) | 2010-05-19 |
IL203714A (en) | 2014-05-28 |
HUE035983T2 (hu) | 2018-06-28 |
JP6077195B2 (ja) | 2017-02-08 |
KR101666041B1 (ko) | 2016-10-13 |
CN101873862A (zh) | 2010-10-27 |
HRP20171566T1 (hr) | 2017-11-17 |
HK1148688A1 (en) | 2011-09-16 |
CN101873862B (zh) | 2014-10-01 |
AU2008285595B2 (en) | 2012-08-09 |
WO2009019317A1 (fr) | 2009-02-12 |
EP2185164B1 (fr) | 2017-08-30 |
JP6352996B2 (ja) | 2018-07-04 |
AU2008285595A1 (en) | 2009-02-12 |
JP2016196517A (ja) | 2016-11-24 |
ES2649761T3 (es) | 2018-01-15 |
CA2695478A1 (fr) | 2009-02-12 |
FR2919804A1 (fr) | 2009-02-13 |
US9364504B2 (en) | 2016-06-14 |
US10780151B2 (en) | 2020-09-22 |
JP2010535744A (ja) | 2010-11-25 |
US20180344822A1 (en) | 2018-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR2919804B1 (fr) | Composition et vaccin therapeutique anti-tumoral | |
CY1123435T1 (el) | Anti-pd-l1 αντισωματα και χρησεις αυτων | |
MX363307B (es) | Plataformas para suministro de antigenos. | |
BR112017009398A2 (pt) | moléculas de ligação específicas para cd73 e seus usos | |
EP3616716A3 (fr) | Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations | |
TR201802380T4 (tr) | Benzonaftiridin içeren aşılar. | |
MY187161A (en) | Antibodies that potently neutralize hepatitis b virus and uses thereof | |
WO2008033966A3 (fr) | Particules de réplicon d'alphavirus correspondant à des antigènes de protéines utilisées en qualité d'adjuvants immunologiques | |
WO2014153056A8 (fr) | Traitement anticancéreux à l'aide d'anticorps qui se lient à grp78 de surface cellulaire | |
WO2014028560A3 (fr) | Anticorps bispécifiques redirigés contre des cellules t pour le traitement de maladies | |
UA118332C2 (uk) | Білок, що зв'язує антиген cd27l | |
EA201070200A1 (ru) | Композиции, содержащие пневмококковые антигены | |
TR200701350T1 (tr) | Bazı aminoalkil glukozaminit fosfat bileşikleri ve bunların kullanımları | |
WO2006037979A3 (fr) | Nanoparticules comprenant des antigenes et des adjuvants et structures immunogenes | |
WO2008039874A3 (fr) | Vaccins comprenant des antigènes de cellules souches cancéreuses et procédés | |
WO2007067681A3 (fr) | Compositions et méthodes immunostimulatoires | |
EA201300322A1 (ru) | Композиция опухолеассоциированных пептидов и относящаяся к ним противораковая вакцина | |
WO2013177214A3 (fr) | Focalisation d'épitope par concentration de surface effective variable d'antigène | |
WO2010033274A3 (fr) | Adjuvants de nanoémulsion | |
WO2010017317A3 (fr) | Utilisation d’inhibiteurs de mtor pour augmenter les réponses immunitaires de lymphocytes t | |
EP4272750A3 (fr) | Antigènes de protéine qui confèrent une protection contre une colonisation et/ou une maladie pneumococcique | |
WO2009114085A3 (fr) | Immunothérapie à base de cellules cancéreuses allogéniques | |
WO2015112749A3 (fr) | Procedes et compositions pour une therapie induite par des anticorps et des cellules dendritiques chargees d'anticorps | |
WO2008034074A3 (fr) | Utilisation de cyclophosphamide à doses élevées en combinaison avec des vaccins anti-idiotypiques dans le traitement anticancéreux | |
MX2009009926A (es) | Anticuerpo tumor-especifico humano monoclonal. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PLFP | Fee payment |
Year of fee payment: 10 |
|
PLFP | Fee payment |
Year of fee payment: 11 |
|
PLFP | Fee payment |
Year of fee payment: 12 |
|
PLFP | Fee payment |
Year of fee payment: 13 |
|
PLFP | Fee payment |
Year of fee payment: 14 |
|
PLFP | Fee payment |
Year of fee payment: 15 |
|
PLFP | Fee payment |
Year of fee payment: 16 |
|
PLFP | Fee payment |
Year of fee payment: 17 |